A New Zealand Neuroimaging Study of Repetitive TranscranialMagnetic Stimulation (rTMS) in Treatment-Resistant Depression as assessed by the Montgomery–Åsberg Depression Rating Scale.

Not Applicable

• Conditions: Major depressive disorder; Mental Health - Depression

• Registration Number: ACTRN12618001953224
• Lead Sponsor: The university of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-12-03
• Study Completion: 2020-03-23
• Last Update Posted: 27 December 2021

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

•Patient is willing and able to give informed consent for participation in the trial
•Male or female, aged 18 years or above
•In the Investigators’ opinion, is able and willing to comply with all trial requirements
•Major depressive disorder for at least three months, as assessed by a Clinical Interview using DSM-IV criteria
•MADRS >20
An inadequate response to at least two antidepressants courses one of which can include the current episode.

Exclusion Criteria

•Contraindications to repetitive transcranial magnetic stimulation, assessed using the University of Auckland safety checklist
•Contraindications for MRI as per the CAMRI screening form
•History of psychosis
•Any unstable medical or neurologic condition
•Planned major changes to psychotropic medication
•Imminent risk of suicide as determined by the CSSRS and clinical interview with a consultant psychiatrist
•Planned or probable use of ECT
•>2 years of depressive episode
•Substance abuse or dependence in previous 6 months
•Any other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial
•Regular use of any medication deemed to be contraindicating as judged by the screening physicians
•Inability to speak or read English
•Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in depressive symptomology measured with the Montgomery-Asberg Depression Rating Scale<br>[At the completion of 20 rTMS treatment sessions (~4 weeks after treatment commences).]

Secondary Outcome Measures

Name	Time	Method
Concentration of GABA in the left dorsalateral prefrontal cortex as measured with magnetic resonance spectroscopy[At the completion of 20 rTMS treatment sessions (~4 weeks after treatment commences).]